Sandbox: sadaf: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 48: | Line 48: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
! rowspan=" | ! rowspan="23" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection | ||
! align="center" style="background:#DCDCDC;" + |'''Gestational thrombocytopenia''' | ! align="center" style="background:#DCDCDC;" + |'''Gestational thrombocytopenia''' | ||
! | ! | ||
Line 427: | Line 427: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="2" align="center" style="background:#DCDCDC;" + |'''Viral infections''' | ! rowspan="2" align="center" style="background:#DCDCDC;" + |'''Viral infections''' | ||
Revision as of 03:08, 13 August 2018
Thrombocytopenia Differential Diagnosis
Differentiating the diseases that can cause thrombocytopenia:
Category | Condition | Clinical manifestations | Para−clinical findings | Gold standard | Associated findings | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | ||||||||||||||||||||||
Lab Findings | Imaging | ||||||||||||||||||||||
Severity | Fever | Bleeding | BP | Other | CBC | PBS | Coagulopathy | ||||||||||||||||
Mechanism | |||||||||||||||||||||||
Infection | Gestational thrombocytopenia | ||||||||||||||||||||||
Chronic liver disease | |||||||||||||||||||||||
portal hypertension | |||||||||||||||||||||||
Hypersplenism | |||||||||||||||||||||||
Immune thrombocytopenia | Antibody-mediated platelet destruction | Moderate to severe | - | Diagnosis of exclusion | |||||||||||||||||||
Congenital platelet disorders | MYH-9 related disorders | ||||||||||||||||||||||
Bernard-Soulier syndrome | |||||||||||||||||||||||
Gray platelet syndrome | |||||||||||||||||||||||
Wiskott-Aldrich syndrome | |||||||||||||||||||||||
Thrombocytopenia with absent radius (TAR) syndrome | |||||||||||||||||||||||
Alport syndrome | |||||||||||||||||||||||
Von Willebrand disease | |||||||||||||||||||||||
Viral infections | rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus | ||||||||||||||||||||||
HIV |
|
||||||||||||||||||||||
Bacterial infections | Sepsis | Direct bone marrow suppression | |||||||||||||||||||||
Helicobacter pylori | Immune thrombocytopenia | ||||||||||||||||||||||
leptospirosis, brucellosis, anaplasmosis, and other tick-borne infections | |||||||||||||||||||||||
Intracellular parasites | Malaria | ||||||||||||||||||||||
Babesiosis | |||||||||||||||||||||||
Medications/toxicity | Drug-induced immune thrombocytopenia |
|
Occurrence of drug-dependent, platelet-reactive antibodies | ||||||||||||||||||||
Heparin-induced thrombocytopenia | |||||||||||||||||||||||
Cytotoxic chemotherapy | |||||||||||||||||||||||
Radiation therapy | Predictable, dose-dependent myelosuppression | ||||||||||||||||||||||
OTC agents | Quinine-containing beverages | ||||||||||||||||||||||
Alcohol | |||||||||||||||||||||||
Malignancy | |||||||||||||||||||||||
Nutrient deficiencies | folate, vitamin B12, copper | an autoimmune mechanism | Mild | ||||||||||||||||||||
Thrombotic microangiopathy (TMA) | Thrombotic thrombocytopenic purpura (TTP) | ||||||||||||||||||||||
Hemolytic uremic syndrome (HUS) | |||||||||||||||||||||||
Drug-induced TMA (DITMA) | |||||||||||||||||||||||
Bone marrow disorders | Myelodysplastic syndromes | ||||||||||||||||||||||
Aplastic anemia | |||||||||||||||||||||||
Acute leukemia | |||||||||||||||||||||||
Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||||||||||||
Rheumatologic/autoimmune disorders | Systemic lupus erythematosus (SLE) | ||||||||||||||||||||||
Antiphospholipid syndrome (APS) | autoantibody-mediated syndrome | ||||||||||||||||||||||
Felty's syndrome | splenomegaly | ||||||||||||||||||||||
vascular | giant capillary hemangioma, | platelet destruction | |||||||||||||||||||||
large aortic aneurysms, | platelet destruction | ||||||||||||||||||||||
cardiopulmonary bypass | platelet destruction | ||||||||||||||||||||||
Post-transfusion purpura | immune-mediated platelet destruction |